MEP25808A - Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals - Google Patents

Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals

Info

Publication number
MEP25808A
MEP25808A MEP-258/08A MEP25808A MEP25808A ME P25808 A MEP25808 A ME P25808A ME P25808 A MEP25808 A ME P25808A ME P25808 A MEP25808 A ME P25808A
Authority
ME
Montenegro
Prior art keywords
formula
compounds
acylated
content
enzyme
Prior art date
Application number
MEP-258/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Hartmut Strobel
Paulus Wohlfart
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MEP25808A publication Critical patent/MEP25808A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MEP-258/08A 2002-08-07 2003-07-24 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals MEP25808A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02017586A EP1388342A1 (fr) 2002-08-07 2002-08-07 Dérivés de cycloalkenylamine condensé avec un hététoaryle et acylé et leur utilisation comme produits pharmaceutiques
PCT/EP2003/008103 WO2004014372A1 (fr) 2002-08-07 2003-07-24 Cycloalcenylamines acylees et heteroaryle-condensees et utilisation de celles-ci comme produits pharmaceutiques

Publications (1)

Publication Number Publication Date
MEP25808A true MEP25808A (en) 2010-06-10

Family

ID=30129194

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-258/08A MEP25808A (en) 2002-08-07 2003-07-24 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals

Country Status (27)

Country Link
EP (2) EP1388342A1 (fr)
JP (1) JP4608315B2 (fr)
KR (1) KR101061727B1 (fr)
CN (1) CN100337626C (fr)
AR (1) AR040790A1 (fr)
AT (1) ATE524178T1 (fr)
AU (1) AU2003251466B2 (fr)
BR (1) BR0313240A (fr)
CA (1) CA2494302C (fr)
DK (1) DK1534277T3 (fr)
ES (1) ES2373651T3 (fr)
HK (1) HK1079427A1 (fr)
HR (1) HRP20050119A2 (fr)
IL (1) IL166494A (fr)
MA (1) MA27331A1 (fr)
ME (1) MEP25808A (fr)
MX (1) MXPA05000833A (fr)
MY (1) MY140840A (fr)
NO (1) NO330011B1 (fr)
NZ (1) NZ538090A (fr)
PL (1) PL212119B1 (fr)
PT (1) PT1534277E (fr)
RS (1) RS52385B (fr)
RU (1) RU2338743C2 (fr)
TW (1) TWI328582B (fr)
WO (1) WO2004014372A1 (fr)
ZA (1) ZA200410274B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004042607A1 (de) 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
EP1741709A1 (fr) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Amides heterocycliques substitués contenant un linker saturé, et leur utilisation comme agent pharmaceutique
EP1741708A1 (fr) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Amides heterocycliques substitués contenant un linker cyclique ou insaturé, et leur utilisation comme agent pharmaceutique
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
EP1905764A1 (fr) * 2006-09-30 2008-04-02 Sanofi-Aventis 2-Phenylbenzimidazoles et leur utilisation comme composés pharmaceutiques
EP1923062A1 (fr) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles et leur utilisation comme agent pharmaceutique
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
EP1939180A1 (fr) 2006-12-20 2008-07-02 sanofi-aventis Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale
EP1942104A1 (fr) 2006-12-20 2008-07-09 sanofi-aventis Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique
EP1939181A1 (fr) 2006-12-27 2008-07-02 sanofi-aventis Carboxamides hétérocycliques et leur utilisation pour la stimulation de l'expression de la NO synthase
EP1964841A1 (fr) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine et son utilisation en tant que produit pharmaceutique
EP1964840A1 (fr) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines et leur utilisation en tant que produits pharmaceutiques
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061763A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
JP2011520997A (ja) 2008-05-29 2011-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 2−アルコキシ置換ジシアノピリジン類およびそれらの使用
AU2009289846B2 (en) * 2008-09-02 2014-10-16 Sanofi-Aventis Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
CN101759683B (zh) * 2008-12-25 2011-12-28 哈尔滨誉衡药业股份有限公司 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
RU2545758C1 (ru) * 2014-03-20 2015-04-10 Общество с ограниченной ответственностью "Алион" Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов
EP3174868B1 (fr) 2014-08-01 2021-08-25 Nuevolution A/S Composés actifs envers des bromodomaines
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
SG11202002032SA (en) 2017-09-22 2020-04-29 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
IL272667B (en) 2017-10-18 2022-09-01 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
SG11202004143XA (en) 2017-11-06 2020-06-29 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
WO2019102494A1 (fr) 2017-11-24 2019-05-31 Jubilant Biosys Limited Composés hétérocycliques utilisés en tant qu'inhibiteurs de prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325234A (ja) * 1995-05-30 1996-12-10 Yamanouchi Pharmaceut Co Ltd 安息香酸誘導体又はその塩
BR9909666A (pt) * 1998-03-26 2001-09-11 Japan Tobacco Inc Derivados de amida e antagonistas de nociceptina
JP3013989B2 (ja) * 1998-03-26 2000-02-28 日本たばこ産業株式会社 アミド誘導体及びノシセプチンアンタゴニスト
AU2001244088A1 (en) * 2000-03-17 2001-09-24 Boehringer Ingelheim International G.M.B.H Condensed imidazoles as histamine h3 receptor ligands
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
MY136316A (en) * 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals

Also Published As

Publication number Publication date
KR101061727B1 (ko) 2011-09-05
CN100337626C (zh) 2007-09-19
MXPA05000833A (es) 2005-04-19
PL373279A1 (en) 2005-08-22
IL166494A (en) 2011-12-29
JP2005538124A (ja) 2005-12-15
CN1674895A (zh) 2005-09-28
NO20050830L (no) 2005-02-16
CA2494302C (fr) 2011-11-29
RU2005106292A (ru) 2005-09-10
HRP20050119A2 (en) 2006-05-31
NO330011B1 (no) 2011-02-07
ATE524178T1 (de) 2011-09-15
KR20050059056A (ko) 2005-06-17
ZA200410274B (en) 2006-07-26
BR0313240A (pt) 2005-09-27
ES2373651T3 (es) 2012-02-07
IL166494A0 (en) 2006-01-15
JP4608315B2 (ja) 2011-01-12
EP1388342A1 (fr) 2004-02-11
AR040790A1 (es) 2005-04-20
HK1079427A1 (en) 2006-04-07
TW200412949A (en) 2004-08-01
CA2494302A1 (fr) 2004-02-19
EP1534277A1 (fr) 2005-06-01
TWI328582B (en) 2010-08-11
RU2338743C2 (ru) 2008-11-20
RS52385B (en) 2013-02-28
EP1534277B1 (fr) 2011-09-14
MY140840A (en) 2010-01-29
RS20050097A (en) 2007-06-04
PT1534277E (pt) 2011-12-06
DK1534277T3 (da) 2012-01-09
MA27331A1 (fr) 2005-05-02
AU2003251466B2 (en) 2009-04-23
NZ538090A (en) 2007-02-23
AU2003251466A1 (en) 2004-02-25
PL212119B1 (pl) 2012-08-31
WO2004014372A1 (fr) 2004-02-19

Similar Documents

Publication Publication Date Title
MEP25808A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
MEP60508A (en) Acylated arylcycloalkylamines and their use as pharmaceuticals
IL166493A0 (en) Acylamino-substituted heteroaromatic compounds andtheir use as pharmaceuticals
MEP43008A (en) Indole-2-carboxamides as factor xa inhibitors
NO20031331L (no) Substituerte amino-aza-cykloalkaner anvendelige mot malaria
HUP0303256A2 (hu) Acilezett indanol-aminok és gyógyszerkénti alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
RS70104A (en) Nicotinamide derivatives useful as pde4 inhibitors
HUP0204235A2 (hu) Helyettesített glutárimidek és felhasználásuk IL-12 termelés inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE60110263D1 (de) Oxybenzamidderivate als faktor-xa-inhibitoren
DE602005023887D1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino-chinazolinderivate
WO2006017836A3 (fr) Nouveaux derives de 2-amino-quinazoline utiles en tant qu'inhibiteurs de la $g(b)-secretase (bace)
HRP20041042A2 (en) Novel substituted sulfamate anticonvulsant derivatives
UA84048C2 (ru) Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе
MX2008000019A (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o ciclico, y su uso como productos farmaceuticos.
IS7545A (is) 7-Arýl-3,9-díasabísýkló(3.3.1)nón-6-en afleiður og notkun þeirra sem renín hindra í meðferð á háþrýstingi, hjarta- og æða- eða nýrna sjúkdómum
DE602004028367D1 (de) Neue indolderivate als faktor xa-inhibitoren
MEP54708A (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
MXPA05011267A (es) Derivados de la triaza-y tetraaza-antracenodiona, su preparacion y su uso como productos farmaceuticos.
HUP0104026A2 (hu) 2,3-Diszubsztituált piridin-származékok, eljárás előállításukra, ilyen vegyületeket tartalmazó gyógyászati készítmények és e vegyületek intermedierei
CY1109545T1 (el) Συνθεση της (r) και (s)-αμινοκαρνιτινης και παραγωγων που προκυπτουν απο to d- και l- ασπαρτικο οξυ
DE602004013577D1 (de) TRIAZOLDERIVATE ALS FAKTOR-Xa-INHIBITOREN
MX2008000044A (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmaceuticos.
WO2005042517A3 (fr) Derives de bipiperidinyl utilises comme inhibiteurs des recepteurs de chemokine
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
TW200640910A (en) Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors